Skip to content
Targeting Patients as Sick as Dogs episode artwork

Oct 12, 2017 20 min

Targeting Patients as Sick as Dogs

from The Bio Report Hosted by Levine Media Group

Kindred Biosciences is looking to leverage the billions of dollars that others have invested in approved drugs by modifying, improving, and repurposing them for the animal market. The company believes it can formulate, develop, and win approval for these medicines for between $3 million and $5 million each in a matter of three to five years, and capture markets that range between $10 million and $100 million annually. We spoke to Richard Chin, founder and CEO of Kindred, about the business strategy, the company’s pipeline, and the opportunity created by our willingness to spend big money on our pets.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Targeting Patients as Sick as Dogs

0:00 20:15

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 20 minutes long.

When was this The Bio Report episode published?

This episode was published on October 12, 2017.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.